Gilead Sciences, Inc. · NASDAQ (us_market)
Healthcare · Drug Manufacturers - General · United States
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-03-07$117.41 RISE2025-05-09$96.91 PEAK2025-07-25$116.20 140d | -17.5% 63d | Missed | Missed | — | — | +19.9% 77d | Missed |
DROP2024-03-13$75.94 RISE2024-06-18$63.15 PEAK2024-09-12$83.16 183d | -16.8% 97d | Missed | Missed | — | — | +31.7% 86d | Missed |
DROP2020-09-02$66.79 RISE2020-12-30$56.65 PEAK2021-02-05$68.46 156d | -15.2% 119d | Missed | Missed | — | — | +20.8% 37d | Missed |
DROP2020-07-20$78.08 RISE2020-10-30$58.15 PEAK2021-01-25$68.16 189d | -25.5% 102d | Missed | Missed | — | — | +17.2% 87d | Missed |
The United States market has shown robust growth, with a 1.8% increase over the last week and a remarkable 28% rise over the past year, while earnings are projected to grow by 17% annually. In such an environment, identifying stocks that may be trading below their estimated value can offer investors potential opportunities for capitalizing on future growth.
The United States market has shown robust performance, rising 1.8% over the last week and climbing 28% in the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying stocks that are trading below their estimated value can offer potential opportunities for investors looking to capitalize on market growth while minimizing risk.
David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable Stocks to Invest In. On May 22, 2026, the U.S. Food and Drug Administration approved Hepcludex injection, granted to Gilead Sciences, Inc. (NASDAQ:GILD), to treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis. The FDA said bulevirtide is the […]
The stock market rode a big rally in software stocks to fresh highs on Thursday despite another hot inflation report. The Nasdaq gained 0.9%. The Dow rose 25 points to post a slight gain and eke out a fresh record, too.
Hepcludex is now the first and only approved treatment for HDV patients in the US, marking a significant milestone for HDV patients and the HDV market.
The United States market has shown robust performance, climbing 1.2% in the last week and 29% over the past year, with earnings projected to grow by 17% annually. In such an environment, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential growth at a reasonable price.
The United States market has shown robust performance, climbing 1.2% in the last week and 29% over the past year, with earnings projected to grow by 17% annually. In such an environment, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential growth at a reasonable price.
The Investment Committee debate the latest Calls of the Day.
The United States market has shown robust performance, climbing 1.2% in the last week and rising 29% over the past year, with earnings projected to grow by 17% annually in the coming years. In such a thriving environment, identifying stocks that are trading below their intrinsic value can present attractive opportunities for investors seeking potential long-term gains.
The United States market has shown robust performance, climbing 1.2% in the last week and rising 29% over the past year, with earnings projected to grow by 17% annually in the coming years. In such a thriving environment, identifying stocks that are trading below their intrinsic value can present attractive opportunities for investors seeking potential long-term gains.
The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.
The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the latest developments on the Ebola outbreak, risks to the United States, GLP-1's impact on cancer risks, and more.
Gilead Sciences Inc. (NASDAQ:GILD) is one of the cheap NASDAQ stocks to buy right now. On May 21, Gilead Sciences completed the acquisition of Tubulis GmbH, a Germany-based biotechnology company, for $3.15 billion in upfront payments plus up to $1.85 billion in potential milestone considerations. This strategic move bolsters Gilead’s oncology portfolio by integrating Tubulis’ […]
Gilead Sciences Inc. (NASDAQ:GILD) is one of the cheap NASDAQ stocks to buy right now. On May 21, Gilead Sciences completed the acquisition of Tubulis GmbH, a Germany-based biotechnology company, for $3.15 billion in upfront payments plus up to $1.85 billion in potential milestone considerations. This strategic move bolsters Gilead’s oncology portfolio by integrating Tubulis’ […]
Over the last 7 days, the United States market has risen by 1.1%, contributing to an impressive 29% climb over the past year, with earnings forecasted to grow by 17% annually. In such a robust environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on market growth while considering intrinsic value.
Over the last 7 days, the United States market has risen by 1.1%, contributing to an impressive 29% climb over the past year, with earnings forecasted to grow by 17% annually. In such a robust environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on market growth while considering intrinsic value.
Gilead wins FDA approval for Hepcludex, the first U.S. therapy for chronic HDV, while Trodelvy advances in Europe for TNBC.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| GILD | +2.11% | -10.40% | +9.52% | +22.12% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -0.86% | -4.68% | +12.97% | +9.43% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 71.91M | $10.02B | 0.53% | Added+9.6% | 2026-03-31 |
| StateStreet | passive | 59.86M | $8.34B | 0.29% | Trimmed-0.6% | 2026-03-31 |
| CapResearch | fundamental | 27.13M | $3.78B | 0.59% | Added+7.2% | 2026-03-31 |
| Wellington | fundamental | 13.54M | $1.89B | 0.35% | Trimmed-14.9% | 2026-03-31 |
| RenTech | quant | 2.15M | $300.00M | 0.47% | Trimmed-22.8% | 2026-03-31 |
| DEShaw | quant | 200.9K | $28.00M | 0.02% | Added+4.3% | 2026-03-31 |
| Bridgewater | macro | 180.7K | $25.19M | 0.11% | Trimmed-38.2% | 2026-03-31 |
| TRowePrice | fundamental | 26.25M | $3.66M | 0.42% | Trimmed-5.2% | 2026-03-31 |
| TwoSigma | quant | 13.5K | $1.88M | 0.00% | New | 2026-03-31 |
| Citadel | multi-strat | 8.8K | $1.23M | 0.00% | New | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-27 | GILEAD SCIENCES, INC. | 10% Owner | A Grant / award | 471,698 | $26.50 | +$12.50M |
| 2026-05-18 | Mercier Johanna | Chief Comm & Corp Aff Officer | M Option exercise(deriv) | 25,000 | — | +$0 |
| 2026-05-18 | Mercier Johanna | Chief Comm & Corp Aff Officer | S Open-market sale | 700 | $132.75 | −$92.9K |
| 2026-05-18 | Mercier Johanna | Chief Comm & Corp Aff Officer | S Open-market sale | 8,374 | $132.23 | −$1.11M |
| 2026-05-18 | Mercier Johanna | Chief Comm & Corp Aff Officer | S Open-market sale | 11,177 | $131.19 | −$1.47M |
| 2026-05-18 | Mercier Johanna | Chief Comm & Corp Aff Officer | S Open-market sale | 7,749 | $130.29 | −$1.01M |
| 2026-05-18 | Mercier Johanna | Chief Comm & Corp Aff Officer | M Option exercise | 25,000 | $66.64 | +$1.67M |
| 2026-05-18 | Dickinson Andrew D | Chief Financial Officer | S Open-market sale | 3,000 | $132.27 | −$396.8K |
| 2026-05-04 | Kramer Kelly A. | Director | A Grant / award(deriv) | 4,884 | — | +$0 |
| 2026-05-04 | Kramer Kelly A. | Director | A Grant / award(deriv) | 1,146 | — | +$0 |
| 2026-05-04 | MANWANI HARISH | Director | A Grant / award(deriv) | 4,884 | — | +$0 |
| 2026-05-04 | MANWANI HARISH | Director | F Tax withholding | 224 | $130.84 | −$29.3K |
| 2026-05-04 | MANWANI HARISH | Director | A Grant / award | 1,146 | — | +$0 |
| 2026-05-04 | WELTERS ANTHONY | Director | A Grant / award(deriv) | 4,884 | — | +$0 |
| 2026-05-04 | WELTERS ANTHONY | Director | A Grant / award | 1,146 | — | +$0 |
| 2026-05-04 | Rodriguez Javier | Director | A Grant / award(deriv) | 4,884 | — | +$0 |
| 2026-05-04 | Rodriguez Javier | Director | A Grant / award | 1,146 | — | +$0 |
| 2026-05-04 | LOVE TED W | Director | A Grant / award(deriv) | 4,884 | — | +$0 |
| 2026-05-04 | LOVE TED W | Director | A Grant / award | 1,146 | — | +$0 |
| 2026-05-04 | Horning Sandra | Director | A Grant / award(deriv) | 4,884 | — | +$0 |
| 2026-05-04 | Horning Sandra | Director | A Grant / award | 1,146 | — | +$0 |
| 2026-05-04 | BARTON JACQUELINE K | Director | A Grant / award(deriv) | 4,884 | — | +$0 |
| 2026-05-04 | BARTON JACQUELINE K | Director | A Grant / award | 1,146 | — | +$0 |
| 2026-05-04 | Bluestone Jeffrey | Director | A Grant / award(deriv) | 4,884 | — | +$0 |
| 2026-05-04 | Bluestone Jeffrey | Director | A Grant / award | 1,146 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -6.58 | — | — |
| 2026-05-07 | 1.91 | 2.03 | +6.24% |
| 2026-02-10 | 1.81 | 1.86 | +2.82% |
| 2025-10-30 | 2.14 | 2.47 | +15.68% |
| 2025-08-07 | 1.96 | 2.01 | +2.72% |
| 2025-04-24 | 1.78 | 1.81 | +1.94% |
| 2025-02-11 | 1.70 | 1.90 | +11.73% |
| 2024-11-06 | 1.55 | 2.02 | +30.48% |
| 2024-08-08 | 1.60 | 2.01 | +25.74% |
| 2024-04-25 | -1.52 | -1.32 | +13.11% |
| 2024-02-06 | 1.76 | 1.72 | -2.34% |
| 2023-11-07 | 1.92 | 2.29 | +19.56% |
| 2023-08-03 | 1.64 | 1.34 | -18.25% |
| 2023-04-27 | 1.54 | 1.37 | -10.84% |
| 2023-02-02 | 1.51 | 1.67 | +10.87% |
| 2022-10-27 | 1.43 | 1.90 | +32.88% |